SAN DIEGO, Sept. 7, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that Ted W. Love, M.D., has joined its Board of Directors. Dr. Love most recently served as Executive Vice President and Head of Research and Development and Technical Operations at Onyx Pharmaceuticals, Inc., where he launched four multi-center, global phase 3 studies in two years and played a key role in obtaining in 2012 accelerated approval from the FDA to market Kyprolis™ (carfilzomib).
"We are delighted to welcome Ted to our Board of Directors," stated Jack Lief, Chair of the ADVENTRX Board of Directors. "His extensive leadership and management experience, coupled with his expertise in all aspects of drug development and regulatory affairs will be very valuable to ADVENTRX during this important stage in the Company's development of its lead product candidate."
Dr. Love retired from Onyx in August and will serve as a consultant to that company through December 31, 2012. Prior to joining Onyx in 2010, Dr. Love was President, Chief Executive Officer and Chairman of the Board of Directors at ARCA biopharma, Inc. (formerly Nuvelo, Inc.), which he joined in 2001. Previously, he served as Senior Vice President of Development at Theravance, Inc. Earlier in his career, Dr. Love spent six years at Genentech, Inc. in a number of senior management positions in medical affairs and product development and also served as Chairman of Genentech's Product Development Committee. As Vice President, Product Development at Genentech, he managed overall drug development strategy and process, which led to the approval of Rituxan®, Herceptin®, Xolair®, TNKase®, Raptiva® and Avastin®. Dr. Love earned his undergraduate degree in molecular biology from Haverford College and his medical degree at Yale Medical School. He completed his residency and fellowship training in internal medicine and cardiology at Harvard Medical
|SOURCE ADVENTRX Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved